X
[{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate Pharma Confirms Path Forward with FDA to Develop Combination Product","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company\u2019s Sharpened Clinical Development Strategy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Accelagen","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Groundbreaking Clinical Trial Underway to Improve Vision in Individuals with Advanced Retinitis Pigmentosa (RP)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Kiora Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
KIO-301 acts as a reversible 'photoswitch', specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients with retinitis pigmentos.
Lead Product(s):
KIO-301
Therapeutic Area: Genetic Disease
Product Name: KIO-301
Highest Development Status: Phase I
Product Type: Small molecule
Recipient:
Accelagen
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 14, 2023
Details:
KIO-101, also known as PP-001, is a next-generation small molecule inhibitor of Dihydroorotate Dehydrogenase. It has demonstrated picomolar potency with a validated mechanism that may offer greater safety and tolerability than DHODH inhibitors currently in the market.
Lead Product(s):
KIO-101
Therapeutic Area: Ophthalmology
Product Name: PP-001
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 08, 2021
Details:
PP-001, an immune-modulating molecule, is an inhibitor of dihydroorotate dehydrogenase (“DHODH”) and is first-in-class for ophthalmology indications.
Lead Product(s):
PP-001
Therapeutic Area: Ophthalmology
Product Name: PP-001
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 08, 2021
Details:
PP-001, EyeGate’s lead clinical-stage drug product, is a next-generation, non-steroidal, immuno-modulatory and small-molecule inhibitor of Dihydroorotate Dehydrogenase.
Lead Product(s):
PP-001
Therapeutic Area: Ophthalmology
Product Name: PP-001
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $11.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
August 11, 2021
Details:
FDA has granted Aquestive's AQST-108 Fast Track designation, an oral sublingual film formulation that delivers systemic epinephrine in development utilizing proprietary Aquestive PharmFilm ® technologies for treatment of allergic reactions, including anaphylaxis.
Lead Product(s):
Hyaluronic Acid ,Antibiotic
Therapeutic Area: Infections and Infectious Diseases
Product Name: MoxiGel
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 12, 2020